For more than a decade, Merck & Co., Inc. (NYSE: MRK) has been defined by the unprecedented success of Keytruda. As the world’s top-selling drug, this oncology powerhouse has provided the capital and the cover for Merck to dominate the immunotherapy landscape. However, the shadow of 2028—the year Keytruda faces its primary loss of exclusivity (LOE)—has forced a radical evolution in the company’s capital allocation strategy. Merck is no longer just an oncology company; it is mid-pivot toward a diversified future anchored by a robust cardio-pulmonary and respiratory franchise.
This report explores the efficacy of Merck’s multi-billion dollar acquisition spree, specifically focusing on the integration of Acceleron Pharma, Verona Pharma, and Cidara Therapeutics. By assessing the peak sales potential of “non-oncology” anchors like Winrevair and Ohtuvayre against the looming $30 billion revenue void, we evaluate whether this pivot provides a sustainable floor for shareholder value or if the company remains precariously tethered to its oncological roots.
Table of Contents
The Keytruda Paradox: Peak Sales and Patent Cliffs
To understand the necessity of the cardio-pulmonary pivot, one must first quantify the magnitude of the Keytruda cliff. By 2027, Keytruda is projected to generate upwards of $35 billion in annual revenue, representing nearly half of Merck’s total pharmaceutical sales. While Merck has successfully launched Keytruda Qlex (a subcutaneous formulation) to defend its market share, the entry of biosimilars in 2028 is expected to trigger a precipitous decline in U.S. revenue. Analysts suggest a potential 19% drop in the first year alone, followed by steady erosion as government price negotiations under the Inflation Reduction Act (IRA) take hold.
The “Keytruda Paradox” lies in the fact that the drug’s success has made Merck one of the most cash-rich entities in the sector, yet its concentration risk has historically suppressed its price-to-earnings multiple. Management’s response has been an aggressive, science-led M&A strategy designed to build a “pipeline-driven resilience” that can survive the transition from an oncology-led growth model to a multi-pillar revenue base.
The Cardiovascular Pillar: Winrevair and the Acceleron Legacy
The cornerstone of Merck’s cardiovascular ambitions is Winrevair (sotatercept), acquired through the $11.5 billion purchase of Acceleron Pharma. Winrevair represents a paradigm shift in the treatment of Pulmonary Arterial Hypertension (PAH). Unlike traditional vasodilators that merely manage symptoms, Winrevair is the first approved therapy to act as a disease-modifying agent by rebalancing pro-proliferative and anti-proliferative signaling.
In 2025, Winrevair demonstrated explosive growth, with sales reaching $360 million in the third quarter alone, representing over 140% growth. Clinical data from the CADENCE trial and other Phase 3 readouts suggest that Winrevair is not merely a niche player but a foundational therapy. Market forecasts estimate that the PAH market will grow to over $9 billion by 2034, and with its first-mover advantage in disease modification, Winrevair is positioned to capture a dominant share. Merck expects this single asset to contribute multibillion-dollar annual revenues, serving as a critical offset to oncology stagnation.
The Respiratory Expansion: Ohtuvayre and the Verona Acquisition
In mid-2025, Merck completed its $10 billion acquisition of Verona Pharma, bringing Ohtuvayre (ensifentrine) into its portfolio. This acquisition was a strategic masterstroke aimed at the Chronic Obstructive Pulmonary Disease (COPD) market, which had not seen a first-in-class inhaled mechanism in over two decades. Ohtuvayre is a dual PDE3/PDE4 inhibitor, providing both bronchodilator and anti-inflammatory effects in a single nebulized dose.
The commercial uptake of Ohtuvayre has been remarkably swift. In its first full year of commercialization under Merck’s expansive sales force, the drug has seen a 95% quarter-over-quarter growth in prescriptions. Merck’s strategy involves leveraging Ohtuvayre’s unique profile to target patients who remain symptomatic despite standard-of-care triple therapy. Furthermore, the company is aggressively pursuing lifecycle extensions for Ohtuvayre in asthma and bronchiectasis, potentially tripling its addressable patient population by 2030.
Diversifying Risk: Cidara Therapeutics and the Antiviral Play
The $9.2 billion acquisition of Cidara Therapeutics in late 2025 represents the third leg of Merck’s diversification stool. This deal focuses on CD388, a long-acting antiviral designed for universal influenza prevention. While infectious disease is distinct from cardiovascular health, the Cidara acquisition shares the same strategic DNA: targeting “high-unmet-need” respiratory conditions with first-in-class modalities.
CD388 targets a massive, underserved population of high-risk individuals for whom traditional vaccines are less effective, such as the immunocompromised and those with chronic heart or lung disease. By integrating CD388 into its respiratory portfolio, Merck creates a synergistic ecosystem where its sales teams can engage pulmonologists and cardiologists with a comprehensive suite of preventative and therapeutic options. This “respiratory bundle” strategy is designed to maximize the lifetime value of each healthcare provider relationship.
Quantitative Assessment: Filling the $30 Billion Hole
The central question for investors is whether these non-oncology “blockbusters” can realistically fill the revenue gap left by Keytruda. As of early 2026, Merck has projected a total of $70 billion in potential annual revenue opportunities by the mid-2030s from its new growth drivers. This is double the projected peak sales of Keytruda.
A comparative analysis of growth rates highlights the shift. While Keytruda’s growth is slowing into the high single digits as it nears its peak, Merck’s cardio-pulmonary and respiratory segments are posting double and triple-digit gains. By the mid-2030s, Merck anticipates that non-oncology areas—including cardiometabolic, immunology, and infectious diseases—will contribute approximately 50% of the company’s total revenue.
| Metric | Oncology (Legacy) | Cardio-Respiratory (Pivot) |
|---|---|---|
| Revenue Contribution (2025) | ~$32 Billion | ~$2 Billion |
| Projected Peak (2030+) | Stagnation/Decline | $15 – $20 Billion |
| Market Share Potential | Dominant (Defensive) | High (Growth/Offensive) |
| Key Assets | Keytruda, Welireg | Winrevair, Ohtuvayre, CD388 |
Conclusion: A De-Risked Horizon
Merck’s pivot to cardiovascular and respiratory health is more than a defensive maneuver; it is a fundamental re-engineering of the company’s value proposition. The acquisitions of Verona, Cidara, and Acceleron have provided Merck with a suite of assets that are not only high-margin and patent-protected well into the 2040s but also strategically aligned with the aging global demographic.
While the $30 billion hole left by Keytruda is vast, the combined peak sales potential of Winrevair and Ohtuvayre, coupled with a deep pipeline of oral PCSK9 inhibitors and next-generation antivirals, suggests that Merck is successfully de-risking its future. For shareholders, the “Cardiovascular Pivot” marks the transition from a single-product story to a diversified biopharmaceutical powerhouse capable of sustaining growth long after the Keytruda era concludes.